Pharmacological inhibition of CDK7 and CDK9 suppresses gastrointestinal (colon) cancer progression through modulation of stemness, epithelial-mesenchymal transition, and chemoresistance.

RIPK3 overcomes 5-fluorouracil resistance in colorectal cancer cells via AKT/mTOR-mediated autophagy

RIPK3 enhances the sensitivity of colorectal cancer cells to 5-FU and increases the efficacy of 5-FU in inhibiting cell proliferation, invasion, and migration by activating cellular autophagy through inhibition of the AKT-mTOR signaling pathway, thereby reversing drug resistance in colorectal cancer cells.

Genistein inhibits colorectal cancer progression via regulating the LINC00355/miR-150/SGK1 axis and downstream EGFR/PI3K/AKT and MAPK signaling pathways.

Colorectal cancer (CRC) is a major global malignant tumor with high morbidity and mortality, and current clinical therapies have limited curative effects and obvious adverse reactions. Genistein, a key bioactive isoflavone derived from soybeans, has shown prominent anti-tumor activity, whereas its exact molecular mecha...

Molecular functional evaluation of novel c-myc targeting anticancer compounds in non-small cell lung cancer and colon cancer cells

The c-Myc protein is a key regulator of cell growth, proliferation, and differentiation. Its overexpression or dysregulation is linked to several cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Here, we described ECD, a novel small molecule targeting c-Myc, which disrupts the c-Myc/MA...

Small Molecule Targeted Therapy for Hepatocellular Carcinoma: From Multikinase Inhibition to Cancer Stem Cell Eradication Strategies

: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, posing a significant global health burden. Multikinase inhibitors (MKIs) such as sorafenib and lenvatinib are standard therapies for advanced HCC, yet most patients eventually develop drug resistance and tumor relapse, largely a...

MLN4924 suppresses pancreatic cancer progression and enhances chemosensitivity to gemcitabine by targeting the PTGS2/EGFR-PI3K/Akt/mTOR signaling axis.

Results demonstrate that MLN4924 exerts antitumor effects in pancreatic cancer by targeting the PTGS2-EGFR-PI3K/AKT/mTOR axis, providing a mechanistic rationale for its clinical application in pancreatic cancer therapy.

RETRACTED ARTICLE: Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI -N78 cells